Patent intelligence · US
US 8609088
Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
Patent details — US 8609088
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 17, 2013
- Expiration
- Dec 12, 2033
- Applicant
- Regents of the University of Minnesota
- Claims
- 17
- CPC classes
- A61K, A61K38/46, A61K38/465, A61K38/47
Quick answer
US 8609088 (Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases) is held by Regents of the University of Minnesota. Status: granted. Granted Dec 17, 2013. Expires Dec 12, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Regents of the University of Minnesota
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K38/46, A61K38/465, A61K38/47, A61K9/0043, A61P
More from Regents of the University of Minnesota
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 8609088?
US 8609088 (Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases) is held by Regents of the University of Minnesota. Status: granted. Granted Dec 17, 2013. Expires Dec 12, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8609088?
Regents of the University of Minnesota is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 8609088 expire?
Our index shows an expiration date of Dec 12, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.